Dengue Vaccine Globally
- A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people aged 9 to 45 years. The World Health Organization recommends that the vaccine only be given to persons with confirmed previous dengue virus infection.
- The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not been previously infected with a dengue virus may be at risk of developing severe dengue if they get dengue after being vaccinated.
Dengue Vaccine for U.S. Territories and Freely Associated States
- In May 2019, Dengvaxia® was approvedexternal icon by the U.S. Food and Drug Administration (FDA) in the United States for use in children aged 9 to 16 years with laboratory-confirmed previous dengue virus infection and living in an area with endemic dengue. Dengvaxia is not approved for use in U.S. travelers who are visiting but not living in an area where dengue is endemic.
- In June 2021, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended use of Dengvaxia to prevent dengue in children aged 9 to 16 years, with laboratory-confirmed previous dengue virus infection and living in areas where dengue is endemic,.
- The ACIP is comprised of medical and public health experts who develop recommendations on the use of vaccines in the civilian population of the United States. The recommendations stand as public health guidance for safe use of vaccines and related biological products.
- Dengue is endemic in the U.S. territories of American Samoa, Puerto Rico, and the U.S. Virgin Islands, and freely associated states, including the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.
- Information on the vaccine’s availability in the U.S. territories and freely associated states is pending.
Administration of Dengvaxia
- Three doses of vaccine are required. Each shot is spaced 6 months apart.
Page last reviewed: June 25, 2021